Northland Securities Weighs in on Nephros FY2026 Earnings

Nephros Inc. (NASDAQ:NEPH) – Investment analysts at Northland Securities lifted their FY2026 earnings per share (EPS) estimates for shares of Nephros in a report released on Friday, November 6th. Northland Securities analyst B. Brooks now anticipates that the company will post earnings per share of $0.18 for the year, up from their previous estimate of $0.15. Northland Securities has a “Market Perform” rating and a $4.00 price objective on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.18 per share. Northland Securities also issued estimates for Nephros’ Q3 2027 earnings at $0.07 EPS and FY2027 earnings at $0.32 EPS.

Several other equities research analysts have also commented on the company. Benchmark restated a “speculative buy” rating on shares of Nephros in a research report on Tuesday, August 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a report on Friday, October 30th. Finally, Zacks Research upgraded shares of Nephros to a “hold” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Nephros currently has a consensus rating of “Hold” and an average target price of $4.00.

Nephros Trading Up 7.5%

Shares of NEPH stock opened at $3.00 on Monday. The stock has a 50 day moving average of $3.76 and a 200 day moving average of $3.64. The stock has a market cap of $32.61 million, a P/E ratio of 16.67 and a beta of 1.76. Nephros has a twelve month low of $2.66 and a twelve month high of $6.42.

Nephros (NASDAQ:NEPH) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $5.62 million during the quarter, compared to analyst estimates of $5.49 million. Nephros had a return on equity of 10.60% and a net margin of 8.38%.

Hedge Funds Weigh In On Nephros

Several institutional investors and hedge funds have recently modified their holdings of the business. Navellier & Associates Inc. raised its holdings in Nephros by 179.6% in the 2nd quarter. Navellier & Associates Inc. now owns 53,479 shares of the company’s stock worth $191,000 after purchasing an additional 34,353 shares during the period. De Lisle Partners LLP acquired a new stake in Nephros in the second quarter valued at approximately $62,000. Bard Associates Inc. acquired a new stake in Nephros in the second quarter valued at approximately $421,000. BlackRock Inc. purchased a new stake in shares of Nephros in the second quarter valued at approximately $67,000. Finally, Cornerstone Capital Inc. purchased a new stake in shares of Nephros in the second quarter valued at approximately $459,000. Hedge funds and other institutional investors own 41.10% of the company’s stock.

Nephros Company Profile

Nephros, Inc is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water.

The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.

Nephros also offers commercial water-filtration products for applications such as foodservice, hospitality, commercial buildings and healthcare facilities.